What Should PSA Be After Hormone Therapy?

The ideal PSA after hormone therapy is as close to undetectable as possible, and a growing body of evidence suggests that reaching a nadir below 0.2 ng/mL is one of the strongest predictors of long-term survival. But “undetectable” means different things depending on whether you are on standard androgen deprivation therapy alone or a newer combination regimen, and the number itself tells only part of the story. How quickly PSA drops, how long it stays down, and whether imaging confirms what the blood test implies all shape what your PSA result actually means for your prognosis.

Why the Lowest Point Matters More Than Any Single Reading

Oncologists pay close attention to something called the PSA nadir, the lowest level your PSA reaches during treatment. This is not just a snapshot; it is one of the best early indicators of how well hormone therapy is controlling the cancer. A large meta-analysis pooling individual patient data found that men whose PSA dropped to 0.2 ng/mL or below had a median overall survival of about 93 months, compared with roughly 34 months for those whose nadir stayed above 0.2 ng/mL.¹ That is nearly a threefold difference in survival driven largely by how deeply the treatment suppresses PSA.

Real-world data confirms this pattern and pushes the threshold even lower. In a study of 238 men with metastatic hormone-sensitive prostate cancer, those who achieved a PSA below 0.2 ng/mL had a median survival of 96 months. But the men who reached an even deeper suppression, below 0.02 ng/mL, did better still: their median survival had not yet been reached at the time of analysis, meaning most were still alive.² By contrast, men whose PSA nadir remained above 4.0 ng/mL had a median survival of just 44 months.

A separate analysis from the SEARCH database broke this down with even more granularity for men on androgen deprivation after surgery. Those with an undetectable nadir had a 7% estimated four-year risk of progressing to castration-resistant disease, compared with 27% for those whose nadir landed between 0.01 and 0.2 ng/mL and a striking 93% for those above 0.2 ng/mL.³ The four-year cancer-specific death rate was 2% in the undetectable group versus 42% in the above-0.2 group. These are not modest differences. The nadir is essentially sorting patients into very different risk categories.

How Quickly PSA Falls Also Tells a Story

It is not only how low the PSA goes but how long it takes to get there. The concept of “time to nadir” adds a second layer of prognostic information. In men with metastatic disease receiving first-line hormone therapy, those whose PSA took 19 weeks or longer to reach its lowest point had a median progression-free survival of about 126 weeks, nearly three times the 44 weeks seen in men whose PSA bottomed out more quickly.⁴ Overall survival followed the same pattern: 242 weeks versus 156 weeks.

This might seem counterintuitive. Why would a slower drop be better? A very rapid PSA decline to a floor that is still detectable can reflect a tumor that initially responds but runs out of road quickly, often because resistant cell populations are already present. A more gradual decline to a deeply suppressed level suggests that the tumor biology is more uniformly sensitive to androgen deprivation.

Combining both markers sharpens the picture further. A study of men with metastatic prostate cancer found that those with both a high PSA nadir (above 0.2 ng/mL) and a short time to nadir (under six months) had a dramatically higher risk of progressing to castration-resistant disease compared to men with a low nadir and longer time to nadir.⁵ A multivariate analysis from yet another group confirmed that both nadir PSA and time to nadir were independently correlated with both progression-free survival and overall survival, meaning each one provides information the other does not.⁶

What a Rising PSA Means During Treatment

A PSA that has dropped and then starts climbing again is the most common early signal that the cancer is becoming resistant to hormone therapy. The formal definition of castration-resistant prostate cancer requires three things: the serum testosterone is confirmed to be in the castrate range (below 50 ng/dL), there is a rise of at least 25% over the nadir across two measurements taken at least a week apart, and the absolute PSA value has crossed above 2.0 ng/mL.⁷ All three criteria must be met simultaneously. A PSA blip of 0.3 to 0.5 ng/mL that then settles back down is not necessarily castration resistance, and small fluctuations are common early in treatment.

Early PSA kinetics can also predict trouble before formal castration resistance develops. One study found that having a PSA level still above 1% of your pretreatment value at the three-month mark was an independent predictor of both shorter time to castration resistance and shorter overall survival.⁸ So if you started with a PSA of 100 ng/mL and it is still above 1.0 ng/mL three months in, that is a flag worth discussing with your oncologist, even though 1.0 ng/mL might sound low in absolute terms.

Newer Combination Regimens Push PSA Deeper

Standard ADT with an LHRH agonist or antagonist alone can reduce PSA substantially, but the addition of newer androgen receptor pathway inhibitors is changing the benchmarks. A real-world comparison of patients with metastatic castration-sensitive prostate cancer found that those who achieved at least a 90% reduction in PSA after starting an androgen receptor pathway inhibitor had a 60% lower risk of death compared with those who did not reach that depth of response.⁹ At three years, roughly 72% of those with deep PSA responses were still alive, compared with about 55% of those without. The deep responders were also 46% less likely to progress to castration resistance.

Among the newer agents, there are meaningful differences in how fast and how deeply they suppress PSA. A real-world comparison of apalutamide and enzalutamide found that apalutamide patients reached a 90% or greater PSA reduction at a median of 3.7 months, versus 4.9 months for enzalutamide.¹⁰ Another comparison between apalutamide and abiraterone showed that apalutamide achieved a median nadir PSA of 0.02 ng/mL versus 0.23 ng/mL for abiraterone, and reaching that ultralow nadir was powerfully associated with delayed progression.¹¹

These findings do not mean one drug is automatically better for every patient. Side effect profiles, cost, and individual tumor biology all factor in. But the data make a clear point: the era of combination therapy has pushed the expected PSA nadir lower than what ADT alone typically achieves, and those deeper responses translate into meaningfully better outcomes.

When PSA Stays Low but the Cancer Progresses Anyway

Here is something that catches many patients off guard: a low or stable PSA does not guarantee the cancer is controlled. There is a phenomenon called PSA-radiographic discordance, where imaging shows disease progression even though PSA is not rising. In the PREVAIL trial of enzalutamide for castration-resistant disease, roughly a quarter of patients who had radiographic progression showed no corresponding PSA rise.¹² The discordance was even higher in men with visceral metastases in the lungs or liver, reaching about 34%.

More recent analyses across multiple trials of enzalutamide confirm this is not a rare fluke. In the ARCHES trial of men with metastatic hormone-sensitive disease on enzalutamide plus ADT, about a quarter of those who developed radiographic progression had no PSA rise at all, and over 60% had not met the formal PSA progression criteria.¹³ A registry study using PSMA PET/CT imaging found that about 12% of men with undetectable PSA levels still had detectable radiographic disease progression on sensitive imaging.¹⁴

One biological explanation for this mismatch is neuroendocrine transformation, where prostate cancer cells evolve under the pressure of hormone therapy and shift to a different cell type that no longer depends on androgen receptor signaling. These transformed cells stop producing PSA altogether, so blood tests look reassuringly normal while the cancer grows by a completely different mechanism.¹⁵ Neuroendocrine transformation is uncommon, but it tends to produce aggressive disease and is more frequent in men who have been on potent androgen-directed therapies for an extended time. The practical lesson: PSA is an excellent surveillance tool, but it is not the only one, and imaging remains essential for monitoring advanced disease.

Body Weight Can Distort Your PSA Numbers

If you carry extra weight, your PSA readings may be artificially low. Research has shown that men with higher BMI tend to have lower PSA concentrations, likely because a larger blood volume dilutes the PSA circulating in the bloodstream, a phenomenon sometimes called hemodilution.¹⁶ This effect persists over time and also blunts the rate at which PSA rises. For a man on hormone therapy, this means that a PSA of 0.15 ng/mL in someone who is obese might represent the same tumor activity as a higher value in a leaner man. Oncologists do not routinely adjust PSA for BMI, but the effect is worth knowing about, especially if you are tracking small changes near the low end of the range.

Hormone therapy itself also causes body composition changes that compound this issue. Weight gain and shifts toward more body fat are common side effects of ADT, which means the hemodilution effect can become more pronounced over the course of treatment. If your PSA has been stable at very low levels and you have also gained significant weight, both dynamics could be at work, and a small PSA rise might carry more significance than it appears to on paper.

Intermittent Hormone Therapy and PSA-Based Treatment Breaks

For some men, continuous hormone therapy is not the only option. Intermittent androgen deprivation therapy, where treatment is paused and restarted based on PSA behavior, has been studied as a way to reduce side effects without sacrificing cancer control. A landmark randomized trial enrolled men whose PSA rose above 3 ng/mL after radiation therapy and treated them in eight-month cycles, using PSA levels to determine when to resume therapy after off-treatment intervals.¹⁷

The newest trials are testing intermittent approaches specifically in the era of combination therapy. The EORTC De-escalate trial is investigating whether men with metastatic hormone-sensitive prostate cancer who reach a PSA of 0.2 ng/mL or below within six to twelve months of starting maximum androgen blockade can safely pause treatment. Treatment would restart if PSA climbs back to 50% of its original level or above 5 ng/mL, or if imaging shows progression.¹⁸ The trial’s premise is built directly on the sub-analyses showing that men who reach deep PSA suppression have prolonged survival and might tolerate a break without losing that advantage.

Until results from these ongoing trials mature, intermittent therapy remains somewhat controversial for metastatic disease. But for men with rising PSA after radiation who do not have metastases, the existing evidence supports it as a reasonable alternative to continuous therapy, provided PSA is monitored closely during off-treatment windows. The specific restart triggers vary between protocols, but most rely on the PSA crossing a predetermined threshold, often somewhere between 3 and 10 ng/mL depending on the clinical setting.

PSA Benchmarks After Radiation Versus After Surgery

The expected PSA after hormone therapy depends partly on what came before it. Men who receive ADT after external beam radiation therapy operate under different PSA assumptions than men who receive it after radical prostatectomy. After surgery, the prostate gland is physically gone, so any detectable PSA in the blood comes from residual or recurrent cancer cells. The bar is set very low, and even small amounts of PSA are meaningful.

After radiation therapy, some prostate tissue typically remains, and that tissue can produce small amounts of PSA even if the cancer has been eliminated. Older research established that a PSA in the range of 0.0 to 2.0 ng/mL after radiation suggested adequate cancer control, while levels above 2.0 ng/mL consistently tracked with ongoing cancer activity.¹⁹ This means that a PSA of 0.8 ng/mL after radiation plus ADT can be perfectly acceptable, whereas the same reading in a man who had his prostate removed would warrant investigation.

For men receiving salvage radiation after a post-surgical recurrence, PSA nadir and time to nadir are again powerful predictors. A study of post-prostatectomy patients treated with salvage radiotherapy found that those whose PSA nadir stayed below 0.1 ng/mL had dramatically better outcomes, while a nadir above that threshold was associated with a sevenfold increase in the risk of distant metastasis.²⁰ When the researchers combined nadir value with time to nadir, they could stratify patients into four distinct risk groups, with the favorable group showing an 86% five-year biochemical recurrence-free survival versus just 1% in the high-risk group.

Why There Is No Single “Normal” Number

If you have been searching for a definitive PSA number that means everything is fine, the honest answer is that no universal cutoff exists. The thresholds that matter depend on several overlapping factors: whether your cancer was localized or metastatic at diagnosis, what treatment you received before starting hormone therapy, which combination of agents you are on, and your individual tumor biology. A PSA of 0.05 ng/mL might be terrific for a man on ADT alone with metastatic disease but still a sign of concern for a post-prostatectomy patient on combination therapy where truly undetectable levels are achievable.

What the research converges on is a set of principles rather than a single number. Deeper suppression is better. Faster achievement of deep suppression followed by prolonged stability is better than a quick dip and early rebound. A rising trend, even from a low baseline, always deserves attention. And PSA alone cannot capture the full picture, particularly on potent androgen receptor pathway inhibitors where discordant progression is a known phenomenon. Your oncologist will be tracking these patterns, not just individual readings, and the trajectory over several months tells far more than any single blood draw.